spacer
home > pmps > summer 2008 > taking the counterfeit risk out of traceability
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Taking the Counterfeit Risk Out of Traceability

A drug might go through up to 20 processes before it reaches patients. Since pharmaceutical supply chains are becoming longer, the risk of counterfeits making their way into the market is increasing. Pharmaceutical companies, associations and politicians are demanding track and trace devices for traceability and security against the counterfeiting of pharmaceuticals.

According to prognoses by WHO, the sales generated with counterfeit pharmaceuticals will reach $75 billion by 2010. This significant problem requires an urgent solution to ensure the safety of consumers. A combination of traceability and anti-fake marks could provide the answer.

According to the WHO, a counterfeit drug is a medicine that is deliberately and fraudulently mislabelled with respect to identity or source. A counterfeit might contain a wrong agent, or indeed no active agent at all. Counterfeiting, however, is not only limited to the drugs themselves – often the packaging of pharmaceuticals is also counterfeited.

Genuine pharmaceuticals can be wrongly packaged, so that for instance a patient buying heart pills might take a completely different drug without knowing. The fraud cannot be recognised at first (and sometimes not even at second) sight if the counterfeit drugs and the packaging are just too true to the original.

Besides enormous losses for the pharmaceutical industry, the immediate danger for consumers has become more prevalent. If fake drugs are circulated, this poses serious health risks for patients. In the past few years, the case of counterfeit anti-malarial drugs with the active agent Artesunat was published in the media and again made us aware of the danger of counterfeit drugs. The counterfeits contained either little or none of the Chinese herbs that are used to fight the most dangerous form of malaria.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Nicole Golomb is Marketing and Sales Manager for anti-counterfeit systems at 3S Simons Security Systems GmbH, Germany. She is in charge of the management of the specific customer projects dealing with individual applications of the micro colour-code system SECUTAG® on branded articles. Additionally, Nicole is responsible for the analysis of processing technologies in specific industries and the product protection system’s integration in the different sectors.
spacer
Nicole Golomb
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Teva launches AJOVY for the treatment of migraine with the YpsoMate autoinjector from Ypsomed

Burgdorf – Teva Pharmaceutical Industries Ltd. (Teva), a global leader in generic medicines with innovative treatments in select areas, including central nervous system, pain and respiratory, launches its drug product AJOVY® in the pre-filled YpsoMate 2.25 autoinjector from Ypsomed. AJOVY® is used for the preventive treatment of migraine in adults. The collaboration with Teva marks the first commercial market entry of Ypsomed’s larger 2.25 ml autoinjector YpsoMate 2.25.
More info >>

White Papers

Clinical Trial-Specific Travel Programs as a Patient Retention Tool

For many patients, participating in a clinical trial is a major endeavor. Depending on the protocol requirements, study visits can be exhausting. There are a number of reasons why a patient may choose to participate in a trial only to drop out. Conversely, there are several approaches to proactively try to prevent this from happening. There are various methods professionals implement for patient retention. This white paper explores patient travel services as one patient retention strategy.
More info >>

 
Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement